Abstract
In vitro antitumor activity of various organogallium(III) complexes (1–8) has been tested against CT26CL25, HCT116, SW480 colon cancer cell lines. CV and MTT assays were used to assess on the antiproliferative effect of investigated organogallium(III) complexes. From the investigated complexes, the most active was found to be tetranuclear compound 8 against CT26CL25 cells. Flow cytometric analysis of the CT26CL25 cells upon the treatment with 8 was performed in order to determine the role of apoptosis, caspase activation, autophagy and proliferation rate on the cell death caused with this compound. Results indicate cytotoxic potential of the tetranuclear complex 8 by inducing caspase independent apoptosis and blocking most of the cells before first division.
Keywords: Apoptosis, autophagy, cell division, cisplatin, cytotoxic activity, organogallium(III) complexes.
Graphical Abstract
Anti-Cancer Agents in Medicinal Chemistry
Title:Anticancer Activity of Organogallium(III) Complexes in Colon Cancer Cells
Volume: 16 Issue: 3
Author(s): Milena R. Kaluđerović, Marija Mojić, Santiago Gómez-Ruiz, Sanja Mijatović and Danijela Maksimović-Ivanić
Affiliation:
Keywords: Apoptosis, autophagy, cell division, cisplatin, cytotoxic activity, organogallium(III) complexes.
Abstract: In vitro antitumor activity of various organogallium(III) complexes (1–8) has been tested against CT26CL25, HCT116, SW480 colon cancer cell lines. CV and MTT assays were used to assess on the antiproliferative effect of investigated organogallium(III) complexes. From the investigated complexes, the most active was found to be tetranuclear compound 8 against CT26CL25 cells. Flow cytometric analysis of the CT26CL25 cells upon the treatment with 8 was performed in order to determine the role of apoptosis, caspase activation, autophagy and proliferation rate on the cell death caused with this compound. Results indicate cytotoxic potential of the tetranuclear complex 8 by inducing caspase independent apoptosis and blocking most of the cells before first division.
Export Options
About this article
Cite this article as:
Kaluđerović R. Milena, Mojić Marija, Gómez-Ruiz Santiago, Mijatović Sanja and Maksimović-Ivanić Danijela, Anticancer Activity of Organogallium(III) Complexes in Colon Cancer Cells, Anti-Cancer Agents in Medicinal Chemistry 2016; 16 (3) . https://dx.doi.org/10.2174/1871520615666151007160319
DOI https://dx.doi.org/10.2174/1871520615666151007160319 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Resveratrol and Cancer Treatment: Is Hormesis a Yet Unsolved Matter?
Current Pharmaceutical Design The Recent Progresses on The Improved Therapy of Melanoma by Novel Drug Delivery Systems
Current Drug Targets Macroautophagy as a Target of Cancer Therapy
Current Cancer Therapy Reviews Potential Impacts of Prebiotics and Probiotics on Cancer Prevention
Anti-Cancer Agents in Medicinal Chemistry Differential Effects of Doxazosin on Renin-Angiotensin-System- Regulating Aminopeptidase Activities in Neuroblastoma and Glioma Tumoral Cells
CNS & Neurological Disorders - Drug Targets Inhibition of Sphingomyelin Hydrolysis: Targeting the Lipid Mediator Ceramide as a Key Regulator of Cellular Fate
Current Medicinal Chemistry What Makes Y Family Pols Potential Candidates for Molecular Targeted Therapies and Novel Biotechnological Applications
Current Molecular Medicine Shutting Down the Furnace: Preferential Killing of Cancer Cells with Mitochondrial-Targeting Molecules
Current Medicinal Chemistry Gene Therapy Targeting Nuclear Factor-κB: Towards Clinical Application in Inflammatory Diseases and Cancer
Current Gene Therapy Metabolism of the Endocannabinoids Anandamide and 2-Arachidonoyl Glycerol, A Review, with Emphasis on the Pharmacology of Fatty Acid Amide Hydrolase, A Possible Target for the Treatment of Neurodegenerative Diseases and Pain
Current Medicinal Chemistry - Central Nervous System Agents Targeting the Multidrug ABCG2 Transporter with Flavonoidic Inhibitors: In Vitro Optimization and In Vivo Validation
Current Medicinal Chemistry Role of Alterations in the Apoptotic Machinery in Sensitivity of Cancer Cells to Treatment
Current Pharmaceutical Design Cancer Cell Reprogramming: Stem Cell Differentiation Stage Factors and An Agent Based Model to Optimize Cancer Treatment
Current Pharmaceutical Biotechnology Update Clinical Application of Diffusion Tensor Imaging
Current Medical Imaging Receptor-Based Design of Cytokine Therapeutics
Current Pharmaceutical Biotechnology The Urokinase Receptor in the Central Nervous System
CNS & Neurological Disorders - Drug Targets Overview of Molecular Signal Transduction of Malignant Gliomas and Correlation with Responses to Targeted Therapy Recent advances in Molecular Characterization of Glioblastoma
Current Signal Transduction Therapy Nanostructures for Bypassing Blood Brain Barrier
Current Bioactive Compounds Structure and Ligand Based Drug Design Strategies in the Development of Novel 5- LOX Inhibitors
Current Medicinal Chemistry Lessons Learned from the Irinotecan Metabolic Pathway
Current Medicinal Chemistry